Advagene Biopharma Co., Ltd. (6709.TWO)
TWD 19.7
(-0.51%)
TWD 19.7
(-0.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | 12 Million | - | - | - | - |
| Gross Profit | -12 Million | - | - | - | - |
| Operating Expenses | 93.33 Million | 119.81 Million | 94.42 Million | 75.79 Million | 93.45 Million |
| Selling, General and Administrative Expenses | 20.11 Million | 19.76 Million | 21.74 Million | 20.46 Million | 28.11 Million |
| Research and Development Expenses | 73.21 Million | 100.04 Million | 72.68 Million | 55.32 Million | 70.72 Million |
| Other Expenses | - | 202 Thousand | 340 Thousand | 4.04 Million | - |
| Cost and Expenses | 93.33 Million | 119.81 Million | 94.42 Million | 75.79 Million | 93.45 Million |
| Operating Income | -93.33 Million | -118.29 Million | -92.55 Million | -70.05 Million | -98.84 Million |
| Interest Expense | 36 Thousand | 81 Thousand | 127 Thousand | 107 Thousand | - |
| Income Tax Expense | - | - | - | - | - |
| Earnings before Tax | -92.11 Million | -118.37 Million | -92.68 Million | -70.16 Million | -91.61 Million |
| Net Income | -92.11 Million | -118.37 Million | -92.68 Million | -70.16 Million | -91.61 Million |
| Earnings Per Share Basic | -1.83 | -2.40 | -1.88 | -1.57 | -2.05 |
| Earnings Per Share Diluted | -1.83 | -2.40 | -1.88 | -1.57 | -2.05 |
| Weighted Average Shares Outstanding | 50.39 Million | 49.32 Million | 49.17 Million | 44.72 Million | 44.6 Million |
| Weighted Average Shares Outstanding (Diluted) | 50.39 Million | 49.32 Million | 49.17 Million | 44.72 Million | 44.6 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -80.07 Million | -106.69 Million | -84.83 Million | -62.16 Million | -94.28 Million |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 1.08 Million | - | - | - | - | - |
| Gross Profit | -1.08 Million | - | - | - | - | - |
| Operating Expenses | 16.06 Thousand | 16.06 Thousand | 93.33 Million | 22.96 Thousand | 22.96 Thousand | 23.57 Thousand |
| Selling, General and Administrative Expenses | 4968.50 | 4968.50 | - | 5172.00 | 5172.00 | 4887.50 |
| Research and Development Expenses | 11.09 Thousand | 11.09 Thousand | - | 17.79 Thousand | 17.79 Thousand | 18.81 Thousand |
| Other Expenses | - | - | 245 Thousand | - | - | - |
| Cost and Expenses | 16.06 Thousand | 16.06 Thousand | 93.33 Million | 22.96 Thousand | 22.96 Thousand | 23.57 Thousand |
| Operating Income | -16.06 Thousand | -16.06 Thousand | -92.07 Million | -22.96 Thousand | -22.96 Thousand | -23.69 Thousand |
| Interest Expense | - | - | 36 Thousand | - | - | - |
| Income Tax Expense | 15.68 Million | 15.68 Million | - | 22.71 Million | 22.71 Million | 23.29 Million |
| Earnings before Tax | -15.7 Thousand | -15.7 Thousand | -92.11 Million | -22.74 Thousand | -22.74 Thousand | -23.31 Thousand |
| Net Income | -15.7 Million | -15.7 Million | -92.11 Million | -22.74 Million | -22.74 Million | -23.31 Million |
| Earnings Per Share Basic | -0.30 | -0.30 | - | -0.44 | -0.44 | -0.47 |
| Earnings Per Share Diluted | -0.30 | -0.30 | - | -0.44 | -0.44 | -0.47 |
| Weighted Average Shares Outstanding | 53.23 Million | 53.23 Million | 50.39 Million | 51.43 Million | 51.43 Million | 49.34 Million |
| Weighted Average Shares Outstanding (Diluted) | 53.23 Million | 53.23 Million | 50.39 Million | 51.43 Million | 51.43 Million | 49.34 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -15.51 Thousand | -15.51 Thousand | - | -22.04 Thousand | -22.04 Thousand | -22.61 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
BNIX
MC
HMI
OMINFRAL
JXHLY
ELTR